KBKarina L. Bursch

Karina L. Bursch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karina L. Bursch has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural Genomics Defines PBRM1 Bromodomain Variant Function in ccRCC

    by Karina L. Bursch, Salomão D. Jorge, Audrey E. Catlin, Raymundo Nuñez, Michael D. LeClaire, Jacob Licklider, Raul A. Urrutia, Brian C. Smith

    Polybromo‐1 (PBRM1) modulates chromatin accessibility and transcription via six bromodomains that bind acetyl‐lysine residues on nuclear proteins. PBRM1 variants exist in ~40% of clear cell renal cell carcinoma (ccRCC) cases. PBRM1 loss correlates with improved responses to antiangiogenics and immune checkpoint blockade, which are the standard of care for ccRCC therapy. Missense variants cluster within PBRM1 bromodomains and are present in 16% of ccRCC cases, with unknown impacts on therapeutic response. Since in‐depth biophysical and cellular testing of the hundreds of PBRM1 missense variants reported in ccRCC and other cancer types is intractable, computational approaches can provide actionable variant impact assessments. We employed an integrated structural genomics analysis at the levels of protein sequence (2D), structure (3D), and molecular dynamics (4D) to evaluate the effects of all reported ccRCC‐associated missense variants in the second and fourth bromodomains of PBRM1 (33 total) on molecular fitness (i.e., stability, structural integrity, and ligand binding). We also evaluated the concordance between molecular fitness and biophysical parameters of variant structural integrity (differential scanning fluorimetry, circular dichroism, and 1 H‐NMR spectroscopy) and ligand binding (AlphaScreen and electrophoretic mobility shift assays). Integrated molecular fitness scores correlated with measures of acetylated histone binding, while 3D and integrated molecular fitness scores correlated with measures of thermal stability. This integrated structural genomics analysis accelerates mechanistic understanding of how ccRCC missense variants impact PBRM1 bromodomain structure and function. This knowledge supports future studies correlating specific missense variants with PBRM1 tumor‐suppressive functions and patient responses to antiangiogenics and immune checkpoint blockade to inform ccRCC personalized medicine approaches.

  • Open Access

    Multivalent nucleosome scaffolding by bromodomain and extraterminal domain tandem bromodomains

    by Michael D. Olp, Karina L. Bursch, Sarah L. Wynia-Smith, Raymundo Nuñez, Christopher J. Goetz, Vaughn Jackson, Brian C. Smith


  • Open Access

    Current Trends in Sirtuin Activator and Inhibitor Development

    by Karina L. Bursch, Christopher J. Goetz, Brian C. Smith

    Sirtuins are NAD+-dependent protein deacylases and key metabolic regulators, coupling the cellular energy state with selective lysine deacylation to regulate many downstream cellular processes. Humans encode seven sirtuin isoforms (Sirt1-7) with diverse subcellular localization and deacylase targets. Sirtuins are considered protective anti-aging proteins since increased sirtuin activity is canonically associated with lifespan extension and decreased activity with developing aging-related diseases. However, sirtuins can also assume detrimental cellular roles where increased activity contributes to pathophysiology. Modulation of sirtuin activity by activators and inhibitors thus holds substantial potential for defining the cellular roles of sirtuins in health and disease and developing therapeutics. Instead of being comprehensive, this review discusses the well-characterized sirtuin activators and inhibitors available to date, particularly those with demonstrated selectivity, potency, and cellular activity. This review also provides recommendations regarding the best-in-class sirtuin activators and inhibitors for practical research as sirtuin modulator discovery and refinement evolve.


  • Open Access

    Abstract 1294: Cancer-associated missense mutations in the tumor suppressor Polybromo-1 variably affect protein stability and function

    by Karina Bursch, Christopher Goetz, Raymundo Nunez, Guanming Jiao, Michael Olp, Salomão Jorge, Raul Urrutia, Emily Dykhuizen, Brian Smith

  • Open Access

    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML

    by Marium Khan, John T. Roddy, Jesus R. Hernandez, Karina Bursch, Naveet Bal, Karen S. Carlson, Paul A. Bergl


  • Open Access

    Keratin 19 maintains E-cadherin localization at the cell surface and stabilizes cell-cell adhesion of MCF7 cells

    by Sarah Alsharif, Pooja Sharma, Karina Bursch, Rachel Milliken, Van Lam, Arwa Fallatah, Thuc Phan, Meagan Collins, Priya Dohlman, Sarah Tiufekchiev, et al.

    A cytoskeletal protein keratin 19 (K19) is highly expressed in breast cancer but its effects on breast cancer cell mechanics are unclear. In MCF7 cells where K19 expression is ablated, we found that K19 is required to maintain rounded epithelial-like shape and tight cell-cell adhesion. A loss of K19 also lowered cell surface E-cadherin levels. Inhibiting internalization restored cell-cell adhesion of KRT19 knockout cells, suggesting that E-cadherin internalization contributed to defective adhesion. Ultimately, while K19 inhibited cell migration and invasion, it was required for cells to form colonies in suspension. Our results suggest that K19 stabilizes E-cadherin complexes at the cell membrane to maintain cell-cell adhesion which inhibits cell invasiveness but provides growth and survival advantages for circulating tumor cells.